Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Endpoints framed Novartis's December 2019 termination of ADU-S100 as 'the latest in a long line of setbacks' for Aduro after the $750M 2015 alliance — a clear…
Aduro disclosed Novartis 'removed ADU-S100 (MIW815) from its portfolio based on clinical data generated to date,' explicitly noting the decision was not driven…
Published Phase 1b data confirmed ADU-S100 + spartalizumab achieved only ~10.4% ORR with no expansion cohorts opened — independent peer-reviewed validation of…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Novartis and Aduro entered an up-to-$750M global cancer immunotherapy collaboration targeting the STING pathway. Aduro received $200M upfront plus equity investment with up to $500M+ in milestones plus royalties; the partners co-developed STING agonists with Novartis launching a new immuno-oncology research group. Novartis later terminated work on STING program (2019).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Aduro Biotech, Inc. (STING pathway program) (this deal) | 2015 | $750M | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2015 deals · Novartis AG deals · Oncology deals